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Intravitreal antibiotics are the mainstay of treatment in the management of infectious endophthalmitis. Basic
knowledge of the commonly used intravitreal antibiotics, which includes their pharmacokinetics, half-life, duration
of action and clearance, is essential for elimination of intraocular infection without any iatrogenic adverse effect to
the ocular tissue. Various drugs have been studied over the past century to achieve this goal. We performed a
comprehensive review of the antibiotics which have been used for intravitreal route and the pharmacokinetic
factors influencing the drug delivery and safety profile of these antibiotics. Using online resources like PubMed
and Google Scholar, articles were reviewed. The articles were confined to the English language only. We present
a broad overview of pharmacokinetic concepts fundamental for use of intravitreal antibiotics in endophthalmitis
along with a tabulated compendium of the intravitreal antibiotics using available literature. Recent advances for
increasing bioavailability of antibiotics to the posterior segment with the development of controlled drug delivery
devices are also described.
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Introduction
Endophthalmitis whether exogenous or endogenous is
anatomically and visually devastating for the patient and
always presents a challenge to the treating physician.
The vitreous is a transparent gelatinous avascular body,
rich in collagen and hyaluronic acid, which provides a
good culture medium for the microorganisms to prolif-
erate. The presence of poorly developed local immune
mechanisms also promotes microbial proliferation. For
successful elimination of the infection in endophthalmi-
tis, antibiotics must reach the intraocular space and ad-
jacent ocular tissues. Static and dynamic ocular barriers
which form part of the natural protective mechanisms of
the eye impede the penetration of systemically and top-
ically administered antibiotics. Satisfactory drug concen-
tration in the vitreous can be achieved only by the
intravitreal route. Over the years, intravitreal administration* Correspondence: avinash@lvpei.org
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reproduction in any medium, provided the origof antibiotics has become the mainstay of endophthalmitis
management [1,2]. In the absence of adequate antimicrobial
concentrations, irreversible tissue destruction ensues [3].
Various factors are responsible for the poor penetra-
tion of topical and systemic antibiotics in the vitreous.
Baring a few exceptions like systemically administered
fluoroquinolones and linezolid [3-5], topical and sys-
temic antibiotics do not achieve adequate therapeutic
levels due to various physiological barriers. Topically in-
stilled medicines are diluted by the tear film, causing loss
of significant drug in the lacrimal flow [6]. Further low
molecular weight antibiotics also undergo systemic ab-
sorption from the conjunctival capillaries and the naso-
lacrimal mucosal surfaces, leading to further drop in
bioavailability [7]. The corneal epithelium also has tight
junctions, leading to poor paracellular drug penetration
especially for ionic drugs [8]. The posterior barrier
between the bloodstream and the eye is comprised of
retinal pigment epithelium (RPE) and the tight walls of
retinal capillaries. Unlike retinal capillaries, the vascula-
ture of the choroid has extensive blood flow and leaky
walls. Systemically administered drugs easily gain access
to the choroidal extravascular space, but thereafter,s is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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limited by the RPE and the retinal endothelium [9].
Thus, intravitreal administration serves as the only dir-
ect access to the vitreous cavity by bypassing the blood
retinal barrier and achieving higher concentrations of
drugs for prolonged periods of time [10].
Using online resources like PubMed and Google Scholar,
articles of the antibiotics which have been used for intravit-
real route and the pharmacokinetic factors influencing the
drug delivery and safety profile of these antibiotics were
reviewed. The articles were limited to the English language
only. The keywords searched were endophthalmitis, intra-
vitreal antibiotics and pharmacokinetics.History of intravitreal antibiotics
Experimental studies for treatment of endophthalmitis
in rabbit eyes with intraocular antibiotics like penicillin
and sulphonamides were reported as early as the 1940s
[11]. Intravitreal penicillin was found to have a favourable
though limited effect on traumatic endophthalmitis in
these studies. In the 1970s, Peyman and associates reported
the safety and efficacy of various intravitreal antibiotics in
experimentally induced endophthalmitis in rabbit eyes and
established the recommended doses of various intravitreal
antibiotics in human eyes [12,13]. Favourable results of
treatment of acute postoperative endophthalmitis with
intravitreal antibiotics - vancomycin for staphylococcal
endophthalmitis and aminoglycosides for Gram-negative
endophthalmitis - were reported during the 1970s
[13-15]. However, as the macular toxicity of aminogly-
coside antibiotics became known, ceftazidime, a third-
generation cephalosporin, has become the preferred
alternative [16]. In recent times, alternate antibiotics like
intravitreal piperacillin-tazobactam have been studied
both in animal models and clinically especially in cases of
Enterobacter species and multidrug-resistant Pseudomonas
endophthalmitis with favourable outcomes and have
emerged as a useful alternative to ceftazidime [17-19].Factors influencing antibiotic pharmacokinetics
Intravitreal injection of antibiotics bypasses the various
anatomical and physiological ocular barriers. The drug
diffuses freely in the vitreous cavity and reaches the ret-
inal surface, facilitated by extraocular movements [20].
However, the drug distribution and clearance from the
vitreous are influenced by various factors including ionic
nature, molecular weight of the drug molecule, surgical
status and effect of ocular inflammation. In order to
achieve a sustained therapeutic drug concentration in
the vitreous, the frequency of administration should be
based on the half-life (t1/2). The elimination of drug usu-
ally follows first-order kinetics and is proportional to the
amount of drug available and the volume of the vitreous.Factors influencing the pharmacokinetics of intravitreal
antibiotics have been described below briefly [21].
1. Route of exit: Drug molecules can leave the eye
through the anterior route or the posterior route.
Large molecules are known to leave the eye
predominantly by the passive diffusion across the
vitreous to the anterior chamber and through
Schlemm's canal. These include vancomycin,
aminoglycosides, macrolides and rifampicin. The
posterior route is achieved by active transport in the
capillaries and the retinal pigment epithelium through
which smaller drug molecules like beta-lactams,
clindamycin and fluoroquinolones are cleared [22].
2. Ionic nature: Cationic drugs like vancomycin,
aminoglycosides, erythromycin and rifampicin
undergo clearance by passive diffusion into the
aqueous and leave the eye via the anterior
chamber with a t1/2 of about 24 h [23-25].
Anionic drugs like beta-lactams, cephalosporins
and clindamycin primarily undergo clearance
more rapidly across the blood retinal barrier via
the posterior route and exit the eye via uveal
blood flow [23,24]. This is facilitated by active transport
by the retinal pigment layer pump. Hence, they have
shorter t1/2 of about 8 h. Fluoroquinolones which are
zwitterions are cleared via both routes and hence have
the shortest t1/2 [26,27].
3. Solubility coefficient of the drug: Lipophilic antibiotics
like fluoroquinolones and chloramphenicol can be
transported by passive diffusion, while water-soluble
antibiotics like beta-lactams leave the eye via active
transport [23,24].
4. Status of ocular inflammation: In a non-inflamed
eye, the anterior route is poorly efficient, and
hence, antibiotics (vancomycin, aminoglycosides,
erythromycin and rifampicin) eliminated by this
route show long half-life values. Thus, drugs eliminated
through the anterior route have a faster clearance in an
inflamed eye [25]. For drugs mainly eliminated by the
posterior route (beta-lactams, cephalosporins and
clindamycin) in the case of an inflamed eye, the drug
clearance is retarded due to compromise of the retinal
pigment epithelial (RPE) pump or the active transport.
Thus, their half-life is extended [24,28-30].
5. Surgical status of the eye: Clearance of antibiotics
which leave the eye through the anterior route is
more rapid in aphakic eyes, while those which leave
the eye primarily through the posterior route are
cleared more rapidly in vitrectomized eyes. Hegazy
et al. demonstrated retinal toxicity to routinely used
doses of intravitreal antibiotics in silicone oil-filled
eyes. Retinal toxicity was hypothesized due to reduction
of the preretinal space; the drug is confined to the
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bubble and has a longer elimination time. They
recommended using one quarter of the recommended
dose to prevent retinal toxicity [31].
6. Molecular weight: It has been found that the
retention of the drug in the vitreous cavity
increases with increase in relative impermeability
of the retina. As most drugs have a molecular
weight of <500 Da, the half-life is less than 72 h,
requiring repeat injection at that interval depending
on the clinical situation [29].
7. Vitreous liquefaction: If vitreous liquefaction occurs
in the anterior few millimetres and the posterior few
millimetres of the globe, it can lead to the quick
egress of the drug out of the eye, leading to
shortening of its half-life [29].
8. Solution density: If the density of the injected
solution is greater than water, it may settle down
under gravity and cause localized toxicity. This may
require intermittent repositioning of the patient's
head to avoid such an eventuality [32].
9. Frequency of intravitreal antibiotic administration:
The parameters deciding the frequency of repeat
administration of antibiotics are clinical response,
half-life, drug clearance from the eye and surgical
status of the eye. The aim of repeat dosing should
be to optimize the duration of drug exposure to
concentrations above the minimum inhibitory
concentration (MIC), rather than to aim at higher
peak levels. Adequate and safe antibiotic levels can
be better achieved by more frequent rather than
higher dosages [28].
Intravitreal antibiotics: dosing and frequency
Table 1 is a pooled compendium of all published infor-
mation pertaining to the dosing of antibiotics studied
and used for intraocular use in treating experimental en-
dophthalmitis and human eyes [16-59].
Preparation of intravitreal antibiotics
Since the recommended therapeutic dosage of intravit-
real antibiotics is very small and carefully titrated to
prevent retinal toxicity, it is important that this dose is
maintained each time an injection is prepared [39].
Standard protocols have to be followed to ensure accur-
acy, precision as well as reproducibility. The injections
have to be prepared under strict aseptic conditions, under
a certified laminar flow by trained personnel. Preferably, a
printed reference display sheet should be consulted while
preparing injections every time as dilution errors may be
toxic. Mehta et al. reported that vancomycin, ceftazidime
and moxifloxacin prepared in single-use polypropylene sy-
ringes retain potency, sterility and stability up to 24 weeks
when stored at −20°C or −80°C [60].Antibiotic resistance
Indiscriminate and injudicious use and abuse of antibi-
otics have led to the development of resistant bacterial
strains. These include the ocular and nasopharyngeal
flora as well as pathogenic organisms like those causing
keratitis and other ocular infections. Endophthalmitis
caused by these organisms is associated with more se-
vere clinical course and worse visual outcomes [60-62].
This problem of emergence of resistance to standard
antibiotic therapy has forced clinicians to continually
evaluate the best intraocular antibiotics available for the
treatment of bacterial endophthalmitis. In such situa-
tions, the choice of antibiotics is judiciously guided by
culture results and sensitivity patterns of the causative
organism. However, it is also known that in vitro resist-
ance need not be mirrored with in vivo sensitivity and
routinely administered antibiotic doses provide intraocu-
lar drug concentrations which are much higher than the
MICs of most pathogens [61,62]. Knowledge of pharma-
cokinetics, susceptibility patterns and minimum inhibi-
tory concentration serves to properly predict the in vivo
efficacy of antibiotics against target pathogens [62].
Combination therapy
Combination intravitreal therapy is used often in poly-
microbial cases or in empirical treatment of endophthal-
mitis [74]. The physicochemical properties of the various
drugs used for combined injections should be well
known by the physician as they form the basis of pos-
sible adverse drug interactions. The two most common
physicochemical entities that can cause adverse drug in-
teractions are dilution-dependent reactions and acid-
base reactions. Adverse reactions when they occur be-
come evident by physical changes like precipitates, effer-
vescence, haziness and viscosity changes. Precipitates are
avoided by injecting the drugs through different syringes.
Still, the development of subclinical microprecipitates
cannot be ruled out. It has been reported that such pre-
cipitate formation may still allow enough antibacterial
activity of the drug at intravitreal concentrations to be
therapeutically active [75]. Changes in individual drug
half-life post multiple injection have not been studied in
literature.
Future trends
Advances in ocular drug delivery system research are ex-
pected to provide new tools for the treatment of posterior
segment diseases, providing improved drug penetration,
prolonged action, higher efficacy, improved safety and less
invasive administration, resulting in higher patient com-
pliance. Various attempts have been made to improve
drug bioavailability by increasing both drug retention and
drug penetration. Patient compliance and comfort consid-
erations in drug administration are very important factors

















1. Amikacin [16,33-35] Human 400 Anterior NA NA NA 24 to 48 Aerobic GNBs, Pseudomonas
aeruginosa
Rabbit 400 25.5 h <24 h 7 h 24 to 48
2. Ampicillin [36] Human 5,000 Posterior NA NA NA 48 GPC, enterobacteria, therapeutic
option for infections caused by
MDR pathogens
3. Amphotericin-B [37] Human 5 to 10 Posterior 8.9 days NA 1.8 h NA Yeasts, filamentous fungi (resistance
reported for various species of
Aspergillus)Rabbit 10 4.7 days NA NA NA
4. Aztreonam [38] Rabbit 100 Posterior 7.5 h NA NA 12 Excellent activity against family
Enterobacteriaceae; moderate
activity against Pseudomonas
5. Carbenicillin [24] Rabbit 2,000 Anterior 5 h NA NA 15 to 24 Pseudomonas, therapeutic option
for infections caused by MDR
pathogensMonkey 1,000 10 h NA NA NA
6. Cephazolin [24,39] Human 2,250 Posterior 6.5 h 10.5 h NA 24 GPC, GPB, E. coli, Proteus, H. influenza
Rabbit 2,250 6.5 h 10.4 h 6 h NA
7. Ceftazidime [16,40] Human 2,250 Both posterior
and anterior
NA NA NA 48 to 72 Aerobic GNBs, GPBs including
Pseudomonas
Rabbit 2,250 13.8 h 10.1 h 4.7 h 72
8. Ceftriaxone [21,29] Rabbit 2,000 Both posterior
and anterior
NA NA NA 48 to 72 Aerobic GNBs
9. Cefuroxime [21,29] Human
eyes





10. Ciprofloxacin [26,28] Human 100 Both anterior
and posterior




Rabbit 100 2.2 h NA NA NA
11. Clarithromycin [41] Rabbit <1,000 Posterior 2 h NA NA NA GPC, GPB, Chlamydia, Toxoplasma
gondii
12. Clindamycin [42] Human 1,000 Posterior 40 h NA NA 72 GPCs - staphylococci, pneumococci;
GPBs - Bacillus; GNBs - Bacteroides,
Fusobacterium; resistance - enterococci,
Enterobacteriaceae, Clostridium,
Toxoplasma gondii
























Table 1 Pharmacokinetics of intravitreal antibiotics - recommended dosing and frequency of administration (Continued)
bacteria and Mycobacterium
tuberculosis
14. Daptomycin [44] Rabbit 200 Posterior 42 h NA NA Single dose Gram-positive organisms, MRSA,
VRSA, pneumococci, enterococci
15. Dalfopristine/quinopristine [45] Rabbit 400 Posterior NA NA NA 48 Active against VRSA





17. Fluconazole [47] Rabbit 200 Posterior 3.08 h NA NA NA Yeasts
18. Gentamicin [48,49] Human 200 Anterior 40 to 60 h 20 to 40 h <40 h 72 to 96 Aerobic GNBs
Rabbit 40 to 70 32 h 19 h 12 h NA
19. Imipenem [50] Rabbit 50 to 100 Posterior NA NA NA NA MDR GPB, GNBs including
Psedomonas aeruginosa,
therapeutic option for
infections caused by MDR
pathogens
20. Linezolid [5,51] Rabbit 400 NA 2 h NA NA NA Aerobic GPC including MRSA and
vancomycin-resistant enterococci
21. Moxifloxacin [52] Rabbit 200 Both anterior
and posterior
1.72 h Prolonged NA 12 Broad-spectrum activity against
Gram-positive and Gram-negative
organisms
22. Ofloxacin [27] Rabbit 200 to 500 Both anterior
and posterior
5.6 h 9.7 h NA 24 Broad-spectrum activity against
Gram-positive and Gram-negative
organisms




Human 225 Posterior NA NA NA NA Effective GNBs, Staphylococcus
epidermidis and Pseudomonas
aeruginosa; therapeutic option for
infections caused by MDR
pathogens
Rabbit <250 NA NA NA NA
25. Sulfamethoxazole/
trimethoprim [52]
Rabbit 1,600 trimethoprim Anterior NA NA NA NA Broad-spectrum antibacterial activity;
Toxoplasma gondii
26. Tobramycin [53] Human 200 to 400 Anterior NA NA NA NA Aerobic Gram-negative organisms
Rabbit 750 NA NA NA 72 to 96
27. Trovafloxacin [54] Rabbit 25 Both anterior
and posterior
NA NA NA 24 to 48 Expanded spectrum against
Gram-positive and
Gram-negative bacteria
28. Vancomycin [25,55-57] Human 1,000 Anterior 25.5 to 56 h 48 h 9.8 h 72 Active against GPCs - MRSA and
MDR Staphylococcus epidermidis






















Table 1 Pharmacokinetics of intravitreal antibiotics - recommended dosing and frequency of administration (Continued)
29. Voriconazole [58] Human 50 to 200 Posterior 2.5 to 6.5 h NA NA NA Broad-spectrum activity against
moulds and yeasts
Rabbit 25 2.5 h NA NA NA
30. Meropenem [73] Human Posterior 2.6 h NA NA NA Pseudomonas, Bacteroides,
Clostridia, Listeria,
EnterobacteriaceaeRabbit 0.5
GPC, Gram-positive cocci; GPB, Gram-positive bacilli; GNB, Gram-negative bacilli, GNC, Gram-negative cocci; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; VRSA, vancomycin-resistant
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attempts can be divided into two main categories: bio-
availability improvement and controlled release drug de-
livery. The first category includes gels, emulsions, viscosity
enhancers, pro-drugs, liposomes and iontophoresis. The
second category includes various types of polymeric in-
serts, implants and nanoparticles.
A pro-drug is defined as an inactive species obtained
by chemical modifications of the active drug which,
when delivered, will release the active drug essentially in
a single step (i.e. enzymatic conversion). Usually, oph-
thalmic pro-drugs are lipophilic esters or diesters with
better permeability than the parent compound. Lipophi-
licity increases uptake of the pro-drug across lipophilic
membranes which otherwise act as a barrier to hydro-
philic drugs. If the drug is incorporated into a polymeric
vehicle which controls the release of the pro-drug, a
sustained delivery of the drug to the retina and vitreous
layers may be possible [65].
Liposomes are vesicles composed of one or more
phospholipid bilayers separated by aqueous compart-
ments. Liposomes can encapsulate hydrophilic drugs in
the aqueous cavity or introduce hydrophobic drugs into
the membrane as a component. They act as reservoir-
type carriers and possess qualities which can make them
ideal for certain posterior segment uses [66,67]. Intravi-
treally administered liposomal systems could both
significantly increase drug half-life and minimize the
intraocular side effects of drugs used (i.e. ganciclovir
and 5-fluorouridine). Intravitreal injection of liposomes
containing a lipid pro-drug of ganciclovir inhibited CMV
retinitis in rabbits [68,69].
The mechanism of iontophoresis involves applying an
electrical current to an ionisable substance to increase
its mobility across a surface. The EyeGate II Delivery
System (EGDS; EyeGate Pharmaceuticals, Inc., Waltham,
MA, USA), a novel iontophoretic system, has been
designed to achieve optimal therapeutic levels of drug in
the anterior and posterior segments of the eye, while
simultaneously minimizing systemic distribution [70].
The system consists of an inert electrode which elec-
trolyzes water to produce hydronium ions. These hy-
dronium ions propel charged drug molecules. Studies
demonstrating safety and efficacy profile show promise
for the future [71].
Nanoparticles are defined as particles with a diameter
of less than 1 nm (10−9 m) consisting of various bio-
degradable materials, such as natural or synthetic poly-
mers, lipids, phospholipids and metals. Studies have
shown that nanoparticles of different sizes and electric
charges, when injected into the vitreous, migrate through
the retinal layers and tend to accumulate in the retinal
pigment epithelium (RPE) cells up to 4 months after a
single intravenous injection [72].Pharmacokinetics, safety and efficacy of newer antibi-
otics and antifungals need to be continually explored
and established in view of the emerging multidrug and
sometimes pan-drug resistance amongst organisms caus-
ing systemic and ocular infections [62]. For sustained
drug delivery and minimizing chances of retinal toxicity,
intravitreal drug effects of delivering drugs in liposomes
or microspheres have been studied which could provide
therapeutic drug levels for up to a month [63,64]. Non-
biodegradable and biodegradable devices or implants
have been investigated [65-67]. Utility of pro-drugs, per-
meability enhancers, particulate drug delivery systems
xand iontophoresis is currently being explored for sus-
tained intraocular drug delivery [66,67].
Conclusions
The management of infectious endophthalmitis has
evolved from the usage of systemic antibiotics in the
past to the current use of intravitreal antibiotics, pav-
ing the way for nanotechnology in drug delivery in the
future. Successful management of endophthalmitis could
be enhanced by better understanding of pharmacokinetics
of intravitreal antibiotics. Emergence of drug resistance
amongst bacteria remains a matter of concern.
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